TrialJournal of hematology & oncology2021

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.

Marie Maerevoet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.